ArticleNigerian medical journal : journal of the Nigeria Medical Association
Profile of Lung Cancer in two Niger Delta States of Nigeria: An Evaluation of 43 Cases.
Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The data on the epidemiology of lung cancer in Niger delta states is scarce. Therefore, this study aims to determine the epidemiological profile of lung cancer in two Niger Delta states in Nigeria. Methodology: This was a retrospective analysis of all patients managed for histologically diagnosed lung cancer from Jan 2014 to Dec 2019 at two tertiary hospitals in Niger Delta states of Nigeria. The demographics, diagnoses, results of investigations, and outcomes were analysed using descriptive statistics. Results: Forty-three patients were reviewed with a male-to-female ratio of 1.5:1 and an age range between 13-89 years with a mean of 53.5+17.0 years. The following number of patients; 1(2.3%), 26(60.5%), 4 (9.3%) and 12(27.9%) were distributed according into the following age groups ;< 20, 20-59, 60-64 and >65 respectively. Eleven (25.6%) patients were smokers. The commonest symptoms were dyspnoea in 39(90.7%), cough in 35(81.4%), weight loss in 29(67.4%), chest pain in 28(65.1%), and change in voice (hoarseness of voice) in 8(18.6%); while the signs were respiratory distress in 33(76.7%), digital clubbing in 8(18.6%), superior vena cava syndrome in 2(4.7%).The left lung was commonly affected in 24(55.8%) patients, and the left upper lobe was the most common in 21 (20.2%), while the right upper lobe was the least in 13(12.6%) patients. The histological types were Adenocarcinoma in 26(60.5%), squamous cell carcinoma in 15(34.9%) patients, and small cell carcinoma in 2(4.7%) patients. Fifteen (34.9%) patients had elevated platelets. The modalities of pathologic diagnoses were: Mini-Thoracotomy10 (23.3%), Tru-cut biopsy 28 (65.1%), and Bronchoscopy 5 (11.6%).The mortality rate after six months following lung cancer diagnosis was 7(16.2%). Conclusion: In our environment, lung cancer may have a bimodal distribution, peaking in the middle age group and elderly patients who were mainly non-smokers. Elevation of platelets was observed in a significant number of patients.
Indexed as
Identifiers
38867745PMC11165322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.